iShares DJ Medical Devices E.T.F.

IHI-N

NYSEARCA:IHI

274.98
1.52 (0.56%)

Analysis and Opinions about IHI-N

Signal
Opinion
Expert
BUY
BUY
December 27, 2019
He likes medical devices a lot. The ETF looks good with reasonable MER. Once the rhetoric from the presidential campaign subsides, it’ll probably have more smooth sailing.
Show full opinionHide full opinion
He likes medical devices a lot. The ETF looks good with reasonable MER. Once the rhetoric from the presidential campaign subsides, it’ll probably have more smooth sailing.
PAST TOP PICK
PAST TOP PICK
October 3, 2019
(A Top Pick Oct 16/18, Up 16%) It continues to work. Everything is going right with this one. It is not a defensive name and while he likes it, he would not have more than a few percent of it in the market.
Show full opinionHide full opinion
(A Top Pick Oct 16/18, Up 16%) It continues to work. Everything is going right with this one. It is not a defensive name and while he likes it, he would not have more than a few percent of it in the market.
TOP PICK
TOP PICK
October 3, 2019
He loves it. It was flat over the last quarter. He is sticking with it.
Show full opinionHide full opinion
He loves it. It was flat over the last quarter. He is sticking with it.
PAST TOP PICK
PAST TOP PICK
September 13, 2019

(A Top Pick Aug 15/18, Up 20%) A good way to play pharma without the litigation problems. For a Canadian one, it would be ZUH. Medical devices have done very well, and wish he had more.

Show full opinionHide full opinion

(A Top Pick Aug 15/18, Up 20%) A good way to play pharma without the litigation problems. For a Canadian one, it would be ZUH. Medical devices have done very well, and wish he had more.

TOP PICK
TOP PICK
September 11, 2019
A perennial favorite for him. Worldwide hospital spending, global spending and Type II diabetes on the rise all make this a good holding. It is fairly high beta, so if the market falls this will fall too. Yield 0.31%
Show full opinionHide full opinion
A perennial favorite for him. Worldwide hospital spending, global spending and Type II diabetes on the rise all make this a good holding. It is fairly high beta, so if the market falls this will fall too. Yield 0.31%
TOP PICK
TOP PICK
August 7, 2019
The only area of healthcare he remains invested in. The demographics are creating tailwinds. An aging population and growing obesity is good for this. Good cash flow holdings and good diversification. Yield 0.32%
Show full opinionHide full opinion
The only area of healthcare he remains invested in. The demographics are creating tailwinds. An aging population and growing obesity is good for this. Good cash flow holdings and good diversification. Yield 0.32%
PAST TOP PICK
PAST TOP PICK
July 10, 2019
(A Top Pick Jul 11/18, Up 19%) A great example of demographic and diabetes trends that has created huge growth in demand. A sad, but profitable story. Not a defensive stock and has beta with the market.
Show full opinionHide full opinion
(A Top Pick Jul 11/18, Up 19%) A great example of demographic and diabetes trends that has created huge growth in demand. A sad, but profitable story. Not a defensive stock and has beta with the market.
PAST TOP PICK
PAST TOP PICK
June 5, 2019
(A Top Pick Jun 08/18, Up 11%) He continues to love holding this. Worldwide hospital spending continues to increase.
Show full opinionHide full opinion
(A Top Pick Jun 08/18, Up 11%) He continues to love holding this. Worldwide hospital spending continues to increase.
BUY
BUY
May 9, 2019
He likes this. Medical devices play to an aging demographic. The risk is political intereference with governments issuing new laws that interfere with this sector.
Show full opinionHide full opinion
He likes this. Medical devices play to an aging demographic. The risk is political intereference with governments issuing new laws that interfere with this sector.
PAST TOP PICK
PAST TOP PICK
May 8, 2019
(A Top Pick May 09/18, Up 16%) He sees this continuing to be a good performer. It will follow the market up and down, but will do a little better in the long run. The ETF helps reduce the risk of picking a single company. He has backed away from healthcare, but still still holds this.
Show full opinionHide full opinion
(A Top Pick May 09/18, Up 16%) He sees this continuing to be a good performer. It will follow the market up and down, but will do a little better in the long run. The ETF helps reduce the risk of picking a single company. He has backed away from healthcare, but still still holds this.
PAST TOP PICK
PAST TOP PICK
April 10, 2019
(A Top Pick Apr 11/18, Up 25%) It is high quality with a 1.0 beta. He would stick with it as the fundamental still hold true -- aging population, diabetes, etc. There are 29 million US adults with Type 2 diabetes and another 84 million are pre-diabetic -- almost 1 in 3 adults.
Show full opinionHide full opinion
(A Top Pick Apr 11/18, Up 25%) It is high quality with a 1.0 beta. He would stick with it as the fundamental still hold true -- aging population, diabetes, etc. There are 29 million US adults with Type 2 diabetes and another 84 million are pre-diabetic -- almost 1 in 3 adults.
BUY
BUY
February 14, 2019
He likes because it gives diversification away from the big pharma. Nothing wrong with this one.
Show full opinionHide full opinion
He likes because it gives diversification away from the big pharma. Nothing wrong with this one.
John Hood

Unlock Ratings

Price
$220.768
Owned
Unknown
BUY
BUY
February 12, 2019
IXJ vs. IHI IXJ is well-diversified and global and prefers this to IHI. It has an overlay of healthcare technology, which is exciting particularly technology. IHI is fine, too. Buy one-third IXJ and one-third IHI.
Show full opinionHide full opinion
IXJ vs. IHI IXJ is well-diversified and global and prefers this to IHI. It has an overlay of healthcare technology, which is exciting particularly technology. IHI is fine, too. Buy one-third IXJ and one-third IHI.
BUY
BUY
February 12, 2019
IXJ vs. IHI IXJ is well-diversified and global and prefers this to IHI. It has an overlay of healthcare technology, which is exciting particularly technology. IHI is fine, too. Buy one-third IXJ and one-third IHI.
Show full opinionHide full opinion
IXJ vs. IHI IXJ is well-diversified and global and prefers this to IHI. It has an overlay of healthcare technology, which is exciting particularly technology. IHI is fine, too. Buy one-third IXJ and one-third IHI.
PAST TOP PICK
PAST TOP PICK
February 8, 2019
(A Top Pick Nov 23/18, Up 6%) Nov.25-Feb.14 is seasonality which coincides with several healthcare conferences. These medical stocks are still outperforming the market. He took profits.
Show full opinionHide full opinion
(A Top Pick Nov 23/18, Up 6%) Nov.25-Feb.14 is seasonality which coincides with several healthcare conferences. These medical stocks are still outperforming the market. He took profits.
Showing 1 to 15 of 37 entries